Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/05/22
Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 02/28/22
Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate CancerGlobeNewsWire • 02/17/22
Cardurion Pharmaceuticals Enhances Leadership Team with Appointment of Marcia Moore as Chief Operating OfficerBusiness Wire • 02/16/22
Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU MeetingGlobeNewsWire • 02/14/22
Arvinas, Pfizer's ARV-471 Shows Clinical Benefit Rate Of 40% In Pretreated Breast Cancer PatientsBenzinga • 12/10/21
Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast CancerGlobeNewsWire • 12/10/21
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer SymposiumGlobeNewsWire • 11/19/21
Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/03/21